US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Ryder

197.55

-2.3300-1.17%

Volume:303.32K

Turnover:60.21M

Market Cap:7.75B

PE:16.55

High:201.20

Open:198.86

Low:197.16

Close:199.88

52wk High:230.39

52wk Low:125.54

Shares:39.21M

Float Shares:38.07M

Volume Ratio:0.77

T/O Rate:0.80%

Dividend:3.54

Dividend Rate:1.79%

EPS(TTM):11.94

EPS(LYR):11.94

ROE:16.24%

ROA:3.97%

PB:2.54

PE(LYR):16.55

Loading ...

Overview Company News Filings

Press Release: Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

Press Release: Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

Press Release: MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures

Press Release: Park Aerospace Corp. Declares Cash Dividend

Press Release: Progressive Announces Quarterly Common Share Dividend

Press Release: Mineros S.A. to Acquire a Gold Exploration Project in Tolima, Colombia

Press Release: Byrna Technologies Announces Preliminary Fiscal First Quarter Revenues of $29.0 Million

Press Release: Korro Announces Oversubscribed $85 Million Private Placement

Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Press Release: Chemtrade Logistics Income Fund Announces Filing of Audited Financial Statements for 2025

Press Release: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy(R) (epinephrine nasal spray) Commercialization

Press Release: Alliance Laundry Systems Acquires Super Laundry in New York

Press Release: RBI Recommends Shareholders Reject NYSB's "Mini-tender Offer"

Press Release: Orexo changes the organizational structure and management team to increase focus on development of new products

Press Release: Broadridge Declares Quarterly Dividend of $0.975 Per Share

Press Release: Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Press Release: CARsgen Therapeutics Announces 2025 Annual Results

Press Release: Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

Press Release: Bel Fuse Inc. Announces Acquisition of dataMate, an advanced ethernet and broadband business, from Methode Electronics Inc

Press Release: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/R/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"R","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"R\",,,,,undefined,":{"symbol":"R","market":"US","secType":"STK","nameCN":"Ryder","latestPrice":197.55,"timestamp":1774641600000,"preClose":199.88,"halted":0,"volume":303316,"delay":0,"changeRate":-0.011656994196517832,"floatShares":38073300,"shares":39205715,"eps":11.937799,"marketStatus":"Pre-Mkt","change":-2.33,"latestTime":"03-30 04:14:02 EDT","open":198.86,"high":201.2,"low":197.16,"amount":60209081.35112,"amplitude":0.020212,"askPrice":316.08,"askSize":200,"bidPrice":79.41,"bidSize":100,"shortable":3,"etf":0,"ttmEps":11.937799,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774877400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":-292968000000,"exchange":"NYSE","adjPreClose":197.55,"dividendRate":0.01792,"postHourTrading":{"tag":"盘后","latestPrice":197.55,"preClose":197.55,"latestTime":"16:34 EDT","volume":8005,"amount":1581387.75,"timestamp":1774643650985,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7719934078180367,"impliedVol":0.4751,"impliedVolPercentile":0.952},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"R\",,,,,undefined,":{"symbol":"R","floatShares":38073300,"roa":"3.97%","roe":"16.24%","lyrEps":11.937799,"volumeRatio":0.7719934078180367,"shares":39205715,"dividePrice":3.54,"high":201.2,"amplitude":0.020212,"preClose":199.88,"low":197.16,"week52Low":125.54,"pbRate":"2.54","psRate":"0.61","week52High":230.385,"institutionHeld":0.6659,"latestPrice":197.55,"committee":-0.333333,"eps":11.937799,"divideRate":0.01792,"volume":303316,"delay":0,"ttmEps":11.937799,"open":198.86,"prevYearClose":191.39,"prevWeekClose":197.55,"prevMonthClose":221.56,"prevQuarterClose":191.39,"fiveDayClose":191.78,"twentyDayClose":221.56,"sixtyDayClose":192.92,"earningDate":1776873600000,"earningTime":"盘前","dividendPayoutRate":0.28296082308697096,"dividendFrequency":"Q","dividendGrowthYears":10,"dividendGrowthRate":0.13157894736842102,"fiveYearAvgDividendRate":0.02341379230026732},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/R\",params:#limit:5,,,undefined,":[{"date":"2026-04-23","symbol":"R","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/03","expectedEps":2.31,"defaultRemindTime":1776931200000,"name":null,"time":"Pre-Market","dateTimestamp":1776916800000,"actualEps":null},{"date":"2026-02-17","symbol":"R","amount":0.91,"announcedDate":"2026-02-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-02-17","defaultRemindTime":1771338600000,"name":"瑞德系统","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-02-17","currency":"USD","dateTimestamp":1771304400000,"payDate":"2026-03-20"},{"market":"US","date":"2026-02-11","symbol":"R","fiscalQuarterEnding":"2025/12","expectedEps":3.66,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1770786000000,"reportTimeType":"pre","actualEps":3.59},{"date":"2025-11-17","symbol":"R","amount":0.91,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-17","defaultRemindTime":1763389800000,"name":"瑞德系统","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-11-17","currency":"USD","dateTimestamp":1763355600000,"payDate":"2025-12-19"},{"market":"US","date":"2025-10-23","symbol":"R","fiscalQuarterEnding":"2025/09","expectedEps":3.56,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1761192000000,"reportTimeType":"pre","actualEps":3.57}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"R\",market:\"US\",,,undefined,":[{"executeDate":"2016-05-19","recordDate":"2016-05-23","paymentDate":"2016-06-17","value":0.41,"currency":"USD"},{"executeDate":"2016-08-18","recordDate":"2016-08-22","paymentDate":"2016-09-16","value":0.44,"currency":"USD"},{"executeDate":"2016-11-17","recordDate":"2016-11-21","paymentDate":"2016-12-16","value":0.44,"currency":"USD"},{"executeDate":"2017-02-16","recordDate":"2017-02-21","paymentDate":"2017-03-17","value":0.44,"currency":"USD"},{"executeDate":"2017-05-18","recordDate":"2017-05-22","paymentDate":"2017-06-16","value":0.44,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"R\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.5455,"hold":0.2727,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1770955200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/R\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"R","date":"2026-03-27","current":16.548277,"percent":0.873274,"low":-34.630262,"twenty":5.607776,"median":12.030258,"eighty":15.075828,"high":123.038,"avg":15.053786,"sd":23.199392,"marketCap":7836438314},"quantilePoints":[{"date":"2021-04-01","current":-33.933157,"twenty":-6.857111,"median":10.331083,"eighty":16.218817,"marketCap":4139845106},{"date":"2021-04-09","current":-34.04787,"twenty":-6.928836,"median":10.218314,"eighty":16.221611,"marketCap":4153840162},{"date":"2021-04-16","current":-34.32583,"twenty":-7.200998,"median":10.09827,"eighty":16.221611,"marketCap":4187751258},{"date":"2021-04-23","current":-32.988976,"twenty":-7.696196,"median":9.896378,"eighty":16.221611,"marketCap":4024655033},{"date":"2021-04-30","current":112.62731,"twenty":-7.755803,"median":9.861819,"eighty":16.210339,"marketCap":4301011698},{"date":"2021-05-07","current":123.038,"twenty":-7.755803,"median":9.861819,"eighty":16.210339,"marketCap":4698575154},{"date":"2021-05-14","current":120.103822,"twenty":-7.755803,"median":9.861819,"eighty":16.221611,"marketCap":4586524749},{"date":"2021-05-21","current":114.263678,"twenty":-7.755803,"median":9.861819,"eighty":16.281283,"marketCap":4363501347},{"date":"2021-05-28","current":115.378102,"twenty":-7.755803,"median":9.861819,"eighty":16.288377,"marketCap":4406058952},{"date":"2021-06-04","current":113.71352,"twenty":-7.755803,"median":9.861819,"eighty":16.288377,"marketCap":4342491896},{"date":"2021-06-11","current":112.034831,"twenty":-7.755803,"median":9.861819,"eighty":16.289543,"marketCap":4278386135},{"date":"2021-06-18","current":101.243262,"twenty":-7.755803,"median":9.861819,"eighty":16.414731,"marketCap":3866277674},{"date":"2021-06-25","current":106.166474,"twenty":-7.755803,"median":9.861819,"eighty":16.576042,"marketCap":4054285325},{"date":"2021-07-02","current":104.699385,"twenty":-7.755803,"median":9.861819,"eighty":16.620493,"marketCap":3998260123},{"date":"2021-07-09","current":104.191547,"twenty":-7.755803,"median":9.861819,"eighty":16.682515,"marketCap":3978866783},{"date":"2021-07-16","current":100.086518,"twenty":-7.755803,"median":9.861819,"eighty":16.729366,"marketCap":3822103957},{"date":"2021-07-23","current":103.556748,"twenty":-7.755803,"median":9.861819,"eighty":16.762384,"marketCap":3954625109},{"date":"2021-07-30","current":15.665589,"twenty":-7.755803,"median":9.861819,"eighty":16.769077,"marketCap":4094859563},{"date":"2021-08-06","current":15.879538,"twenty":-7.755803,"median":9.861819,"eighty":16.769077,"marketCap":4150784106},{"date":"2021-08-13","current":16.330065,"twenty":-7.755803,"median":9.861819,"eighty":16.769077,"marketCap":4268548288},{"date":"2021-08-20","current":15.305578,"twenty":-7.755803,"median":9.861819,"eighty":16.769077,"marketCap":4000755765},{"date":"2021-08-27","current":16.714761,"twenty":-7.755803,"median":9.861819,"eighty":16.769077,"marketCap":4369104918},{"date":"2021-09-03","current":16.395895,"twenty":-7.751218,"median":9.87728,"eighty":16.767739,"marketCap":4285755840},{"date":"2021-09-10","current":16.046171,"twenty":-7.751218,"median":9.87728,"eighty":16.767739,"marketCap":4194340722},{"date":"2021-09-17","current":16.161374,"twenty":-7.751218,"median":9.87728,"eighty":16.767739,"marketCap":4224453937},{"date":"2021-09-24","current":16.916367,"twenty":-7.751218,"median":9.87728,"eighty":16.7724,"marketCap":4421803045},{"date":"2021-10-01","current":17.126202,"twenty":-7.751218,"median":9.87728,"eighty":16.824146,"marketCap":4476652116},{"date":"2021-10-08","current":17.115916,"twenty":-7.751218,"median":9.87728,"eighty":16.86858,"marketCap":4473963436},{"date":"2021-10-15","current":17.229062,"twenty":-7.751218,"median":9.87728,"eighty":16.897726,"marketCap":4503538916},{"date":"2021-10-22","current":18.296749,"twenty":-7.751218,"median":9.87728,"eighty":16.957122,"marketCap":4782623895},{"date":"2021-10-29","current":12.544258,"twenty":-7.746632,"median":9.89274,"eighty":16.972991,"marketCap":4561242691},{"date":"2021-11-05","current":12.858787,"twenty":-7.746632,"median":9.89274,"eighty":16.972991,"marketCap":4675609342},{"date":"2021-11-12","current":12.99464,"twenty":-7.746632,"median":9.89274,"eighty":16.946201,"marketCap":4725007144},{"date":"2021-11-19","current":12.432031,"twenty":-7.746632,"median":9.89274,"eighty":16.881013,"marketCap":4520435811},{"date":"2021-11-26","current":12.601848,"twenty":-7.746632,"median":9.89274,"eighty":16.848905,"marketCap":4582183064},{"date":"2021-12-03","current":11.712896,"twenty":-7.746632,"median":9.89274,"eighty":16.823699,"marketCap":4258949621},{"date":"2021-12-10","current":11.980172,"twenty":-7.746632,"median":9.89274,"eighty":16.771738,"marketCap":4356134427},{"date":"2021-12-17","current":11.548987,"twenty":-7.746632,"median":9.89274,"eighty":16.734025,"marketCap":4199350099},{"date":"2021-12-23","current":11.717326,"twenty":-7.746632,"median":9.89274,"eighty":16.724457,"marketCap":4260560419},{"date":"2021-12-31","current":12.172139,"twenty":-7.746632,"median":9.89274,"eighty":16.688297,"marketCap":4425935669},{"date":"2022-01-07","current":11.528313,"twenty":-7.742047,"median":9.894559,"eighty":16.645088,"marketCap":4191833042},{"date":"2022-01-14","current":11.66269,"twenty":-7.742047,"median":9.894559,"eighty":16.569237,"marketCap":4240693911},{"date":"2022-01-21","current":11.074978,"twenty":-7.742047,"median":9.894559,"eighty":16.518713,"marketCap":4026994725},{"date":"2022-01-28","current":10.665942,"twenty":-7.742047,"median":9.894559,"eighty":16.390958,"marketCap":3878264386},{"date":"2022-02-04","current":10.595062,"twenty":-7.742047,"median":9.894559,"eighty":16.292436,"marketCap":3852491620},{"date":"2022-02-11","current":10.866768,"twenty":-7.742047,"median":9.894559,"eighty":16.266226,"marketCap":3951287224},{"date":"2022-02-18","current":8.156002,"twenty":-7.742047,"median":9.819077,"eighty":16.167134,"marketCap":4232965038},{"date":"2022-02-25","current":8.041976,"twenty":-7.742047,"median":9.683571,"eighty":16.061394,"marketCap":4173785303},{"date":"2022-03-04","current":8.192283,"twenty":-7.742047,"median":9.408015,"eighty":15.879949,"marketCap":4251794953},{"date":"2022-03-11","current":8.208869,"twenty":-7.742047,"median":8.965509,"eighty":15.706321,"marketCap":4260402915},{"date":"2022-03-18","current":8.2995,"twenty":-7.742047,"median":8.822833,"eighty":15.524465,"marketCap":4307440377},{"date":"2022-03-25","current":7.957709,"twenty":-7.742047,"median":8.777473,"eighty":15.400744,"marketCap":4130051128},{"date":"2022-04-01","current":7.287918,"twenty":-7.742047,"median":8.581191,"eighty":15.306166,"marketCap":3782429545},{"date":"2022-04-08","current":6.216252,"twenty":-7.742047,"median":8.486348,"eighty":15.123407,"marketCap":3226235013},{"date":"2022-04-14","current":6.305886,"twenty":-7.742047,"median":8.400577,"eighty":15.064281,"marketCap":3272754960},{"date":"2022-04-22","current":6.644722,"twenty":-7.742047,"median":8.337941,"eighty":15.019858,"marketCap":3448610584},{"date":"2022-04-29","current":5.552093,"twenty":-7.742047,"median":8.266103,"eighty":15.01151,"marketCap":3574453932},{"date":"2022-05-06","current":5.903169,"twenty":-7.742047,"median":8.228212,"eighty":15.01151,"marketCap":3800478057},{"date":"2022-05-13","current":6.644243,"twenty":-7.742047,"median":8.178807,"eighty":15.01151,"marketCap":4277583282},{"date":"2022-05-20","current":6.306669,"twenty":-7.742047,"median":8.111521,"eighty":15.01151,"marketCap":4060252392},{"date":"2022-05-27","current":6.362269,"twenty":-7.742047,"median":8.052823,"eighty":15.01151,"marketCap":4096048068},{"date":"2022-06-03","current":6.481413,"twenty":-7.742047,"median":8.032181,"eighty":15.01151,"marketCap":4172753088},{"date":"2022-06-10","current":6.150194,"twenty":-7.742047,"median":8.016693,"eighty":15.01151,"marketCap":3959513132},{"date":"2022-06-17","current":5.747488,"twenty":-7.742047,"median":7.956055,"eighty":15.01151,"marketCap":3700250164},{"date":"2022-06-24","current":5.650585,"twenty":-7.746632,"median":7.945333,"eighty":15.013418,"marketCap":3637863415},{"date":"2022-07-01","current":5.726042,"twenty":-7.746632,"median":7.897499,"eighty":15.013418,"marketCap":3686443261},{"date":"2022-07-08","current":5.746694,"twenty":-7.746632,"median":7.835691,"eighty":15.013418,"marketCap":3699738798},{"date":"2022-07-15","current":5.766551,"twenty":-7.746632,"median":7.772142,"eighty":15.013418,"marketCap":3712522968},{"date":"2022-07-22","current":5.926204,"twenty":-7.746632,"median":7.442255,"eighty":15.013418,"marketCap":3815307694},{"date":"2022-07-29","current":5.461894,"twenty":-7.746632,"median":6.699881,"eighty":15.013418,"marketCap":4009565771},{"date":"2022-08-05","current":5.457013,"twenty":-7.746632,"median":6.644722,"eighty":15.013418,"marketCap":4005982145},{"date":"2022-08-12","current":5.788269,"twenty":-7.746632,"median":6.481413,"eighty":15.013418,"marketCap":4249156780},{"date":"2022-08-19","current":5.654372,"twenty":-7.746632,"median":6.388625,"eighty":15.013418,"marketCap":4150863032},{"date":"2022-08-26","current":5.604858,"twenty":-7.746632,"median":6.320172,"eighty":15.013418,"marketCap":4114514824},{"date":"2022-09-02","current":5.186429,"twenty":-7.746632,"median":6.234388,"eighty":15.013418,"marketCap":3807346864},{"date":"2022-09-09","current":5.427723,"twenty":-7.746632,"median":6.204433,"eighty":15.013418,"marketCap":3984480387},{"date":"2022-09-16","current":4.997438,"twenty":-7.746632,"median":6.039787,"eighty":15.013418,"marketCap":3668609335},{"date":"2022-09-23","current":4.66409,"twenty":-7.746632,"median":5.934147,"eighty":15.013418,"marketCap":3423898860},{"date":"2022-09-30","current":5.264535,"twenty":-7.746632,"median":5.891255,"eighty":14.984817,"marketCap":3864684883},{"date":"2022-10-07","current":5.515593,"twenty":-7.746632,"median":5.79038,"eighty":14.962577,"marketCap":4048985659},{"date":"2022-10-14","current":5.330787,"twenty":-7.746632,"median":5.747488,"eighty":14.951585,"marketCap":3913319810},{"date":"2022-10-21","current":5.177363,"twenty":-7.746632,"median":5.716511,"eighty":14.921021,"marketCap":3800691558},{"date":"2022-10-28","current":4.875682,"twenty":-7.746632,"median":5.696654,"eighty":14.896597,"marketCap":4105514216},{"date":"2022-11-04","current":4.97415,"twenty":-7.746632,"median":5.677591,"eighty":14.776301,"marketCap":4188428518},{"date":"2022-11-11","current":5.292233,"twenty":-7.746632,"median":5.663293,"eighty":14.711779,"marketCap":4456266838},{"date":"2022-11-18","current":5.380557,"twenty":-7.746632,"median":5.641848,"eighty":14.711779,"marketCap":4530638454},{"date":"2022-11-25","current":5.732059,"twenty":-7.746632,"median":5.632098,"eighty":14.711779,"marketCap":4826617386},{"date":"2022-12-02","current":5.390702,"twenty":-7.746632,"median":5.616713,"eighty":13.024764,"marketCap":4539181140},{"date":"2022-12-09","current":5.00757,"twenty":-7.746632,"median":5.60073,"eighty":12.852585,"marketCap":4216569129},{"date":"2022-12-16","current":5.043377,"twenty":-7.746632,"median":5.579284,"eighty":12.794995,"marketCap":4246719784},{"date":"2022-12-23","current":5.054119,"twenty":-7.746632,"median":5.556738,"eighty":12.683064,"marketCap":4255764981},{"date":"2022-12-30","current":4.987279,"twenty":-7.746632,"median":5.542093,"eighty":12.55727,"marketCap":4199483758},{"date":"2023-01-06","current":4.977134,"twenty":-7.746632,"median":5.530238,"eighty":12.411068,"marketCap":4190941072},{"date":"2023-01-13","current":5.452767,"twenty":-7.746632,"median":5.515593,"eighty":12.297336,"marketCap":4591442276},{"date":"2023-01-20","current":5.542284,"twenty":-7.746632,"median":5.512803,"eighty":12.262396,"marketCap":4666818914},{"date":"2023-01-27","current":5.635978,"twenty":-7.746632,"median":5.512803,"eighty":12.179012,"marketCap":4745713128},{"date":"2023-02-03","current":5.849625,"twenty":-7.746632,"median":5.504687,"eighty":12.076451,"marketCap":4925612037},{"date":"2023-02-10","current":5.754737,"twenty":-7.746632,"median":5.504687,"eighty":12.026911,"marketCap":4845712801},{"date":"2023-02-17","current":5.263255,"twenty":-7.746632,"median":5.498719,"eighty":11.969767,"marketCap":4563242372},{"date":"2023-02-24","current":5.148999,"twenty":-7.746632,"median":5.492154,"eighty":11.969767,"marketCap":4464182332},{"date":"2023-03-03","current":5.301697,"twenty":-7.746632,"median":5.485925,"eighty":11.969767,"marketCap":4596570983},{"date":"2023-03-10","current":4.857486,"twenty":-7.746632,"median":5.474851,"eighty":11.969767,"marketCap":4211440363},{"date":"2023-03-17","current":4.455455,"twenty":-7.746632,"median":5.452767,"eighty":11.969767,"marketCap":3862879398},{"date":"2023-03-24","current":4.499409,"twenty":-7.746632,"median":5.427723,"eighty":11.969767,"marketCap":3900987688},{"date":"2023-03-31","current":4.783503,"twenty":-7.742047,"median":5.424379,"eighty":11.966298,"marketCap":4147297371},{"date":"2023-04-06","current":4.522458,"twenty":-7.742047,"median":5.424379,"eighty":11.966298,"marketCap":3920971304},{"date":"2023-04-14","current":4.579277,"twenty":-7.746632,"median":5.427723,"eighty":11.969767,"marketCap":3970233240},{"date":"2023-04-21","current":4.639312,"twenty":-7.746632,"median":5.394248,"eighty":11.969767,"marketCap":4022283588},{"date":"2023-04-28","current":4.360113,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3618893391},{"date":"2023-05-05","current":4.456979,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3699292590},{"date":"2023-05-12","current":4.543916,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3771449940},{"date":"2023-05-19","current":4.544476,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3771914863},{"date":"2023-05-26","current":4.48342,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3721238329},{"date":"2023-06-02","current":4.478378,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3717054028},{"date":"2023-06-09","current":4.659306,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3867223940},{"date":"2023-06-16","current":4.628498,"twenty":-7.746632,"median":5.392854,"eighty":11.969767,"marketCap":3841653212},{"date":"2023-06-23","current":4.605532,"twenty":-7.751218,"median":5.393551,"eighty":11.973235,"marketCap":3822591397},{"date":"2023-06-30","current":4.710279,"twenty":-7.755803,"median":5.394248,"eighty":11.976704,"marketCap":3909531872},{"date":"2023-07-07","current":4.670509,"twenty":-7.755803,"median":5.394248,"eighty":11.976704,"marketCap":3876522387},{"date":"2023-07-14","current":4.972428,"twenty":-7.755803,"median":5.394248,"eighty":11.976704,"marketCap":4127115523},{"date":"2023-07-21","current":5.1696,"twenty":-7.755803,"median":5.394248,"eighty":11.976704,"marketCap":4290768183},{"date":"2023-07-28","current":7.905694,"twenty":-7.755803,"median":5.397863,"eighty":11.976704,"marketCap":4529962569},{"date":"2023-08-04","current":7.943832,"twenty":-7.755803,"median":5.452767,"eighty":11.976704,"marketCap":4551815654},{"date":"2023-08-11","current":8.064602,"twenty":-7.755803,"median":5.493974,"eighty":11.976704,"marketCap":4621017093},{"date":"2023-08-18","current":7.684017,"twenty":-7.755803,"median":5.519009,"eighty":11.976704,"marketCap":4402941508},{"date":"2023-08-25","current":7.629988,"twenty":-7.755803,"median":5.540699,"eighty":11.976704,"marketCap":4371982969},{"date":"2023-09-01","current":8.001039,"twenty":-7.755803,"median":5.556738,"eighty":11.976704,"marketCap":4584595283},{"date":"2023-09-08","current":7.796047,"twenty":-7.755803,"median":5.572744,"eighty":11.976704,"marketCap":4467134947},{"date":"2023-09-15","current":8.072548,"twenty":-7.755803,"median":5.598162,"eighty":11.976704,"marketCap":4625569819},{"date":"2023-09-22","current":8.255292,"twenty":-7.755803,"median":5.622292,"eighty":11.976704,"marketCap":4730282521},{"date":"2023-09-29","current":8.464257,"twenty":-7.755803,"median":5.641349,"eighty":11.976704,"marketCap":4850019220},{"date":"2023-10-06","current":7.874707,"twenty":-7.755803,"median":5.654372,"eighty":11.976704,"marketCap":4512206936},{"date":"2023-10-13","current":8.166304,"twenty":-7.755803,"median":5.677385,"eighty":11.976704,"marketCap":4679291988},{"date":"2023-10-20","current":7.969257,"twenty":-7.755803,"median":5.687122,"eighty":11.976704,"marketCap":4566384378},{"date":"2023-10-27","current":8.466638,"twenty":-7.81017,"median":5.70583,"eighty":11.984307,"marketCap":4131719492},{"date":"2023-11-03","current":8.900778,"twenty":-7.81017,"median":5.736104,"eighty":11.984307,"marketCap":4343579814},{"date":"2023-11-10","current":9.098775,"twenty":-7.81017,"median":5.748824,"eighty":11.984307,"marketCap":4440202303},{"date":"2023-11-17","current":9.541998,"twenty":-7.81017,"median":5.774024,"eighty":11.984307,"marketCap":4656494849},{"date":"2023-11-24","current":9.76815,"twenty":-7.81017,"median":5.792649,"eighty":11.984307,"marketCap":4766857234},{"date":"2023-12-01","current":9.730912,"twenty":-7.81017,"median":5.832915,"eighty":11.984307,"marketCap":4748685115},{"date":"2023-12-08","current":9.643721,"twenty":-7.785279,"median":5.902141,"eighty":11.982239,"marketCap":4706135761},{"date":"2023-12-15","current":10.11964,"twenty":-7.785279,"median":5.934147,"eighty":11.982239,"marketCap":4938384315},{"date":"2023-12-22","current":10.650962,"twenty":-7.785279,"median":6.039787,"eighty":11.982239,"marketCap":5197669436},{"date":"2023-12-29","current":10.469313,"twenty":-7.81017,"median":6.186334,"eighty":11.984307,"marketCap":5109024950},{"date":"2024-01-05","current":10.161419,"twenty":-7.835061,"median":6.212148,"eighty":11.986374,"marketCap":4958772546},{"date":"2024-01-12","current":10.035173,"twenty":-7.835061,"median":6.306669,"eighty":11.986374,"marketCap":4897164629},{"date":"2024-01-19","current":10.137805,"twenty":-7.859952,"median":6.350752,"eighty":11.988442,"marketCap":4947248763},{"date":"2024-01-26","current":10.437525,"twenty":-7.835061,"median":6.413898,"eighty":11.986374,"marketCap":5093512165},{"date":"2024-02-02","current":10.526533,"twenty":-7.835061,"median":6.548928,"eighty":11.986374,"marketCap":5136947963},{"date":"2024-02-09","current":10.603733,"twenty":-7.835061,"median":6.662452,"eighty":11.986374,"marketCap":5174621870},{"date":"2024-02-16","current":11.958272,"twenty":-7.835061,"median":6.699881,"eighty":11.992994,"marketCap":4855058498},{"date":"2024-02-23","current":12.181128,"twenty":-7.835061,"median":6.699881,"eighty":12.003352,"marketCap":4945538144},{"date":"2024-03-01","current":12.341207,"twenty":-7.81017,"median":6.732825,"eighty":12.070758,"marketCap":5010530121},{"date":"2024-03-08","current":12.549959,"twenty":-7.81017,"median":6.732825,"eighty":12.1283,"marketCap":5095283172},{"date":"2024-03-15","current":12.315273,"twenty":-7.81017,"median":6.732825,"eighty":12.192966,"marketCap":5000001022},{"date":"2024-03-22","current":12.709973,"twenty":-7.81017,"median":6.732825,"eighty":12.252055,"marketCap":5160248952},{"date":"2024-03-28","current":12.9324,"twenty":-7.81017,"median":6.732825,"eighty":12.27243,"marketCap":5250554416},{"date":"2024-04-05","current":12.824457,"twenty":-7.835061,"median":6.699881,"eighty":12.310529,"marketCap":5206729706},{"date":"2024-04-12","current":12.753586,"twenty":-7.835061,"median":6.699881,"eighty":12.337386,"marketCap":5177955906},{"date":"2024-04-19","current":11.685063,"twenty":-7.835061,"median":6.699881,"eighty":12.340342,"marketCap":4744135543},{"date":"2024-04-26","current":15.244202,"twenty":-7.81017,"median":6.732825,"eighty":12.359817,"marketCap":5365959126},{"date":"2024-05-03","current":15.528093,"twenty":-7.81017,"median":6.732825,"eighty":12.422817,"marketCap":5465888775},{"date":"2024-05-10","current":15.863035,"twenty":-7.81017,"median":6.732825,"eighty":12.516984,"marketCap":5583788228},{"date":"2024-05-17","current":15.561712,"twenty":-7.81017,"median":6.732825,"eighty":12.565399,"marketCap":5477722549},{"date":"2024-05-24","current":14.992685,"twenty":-7.81017,"median":6.732825,"eighty":12.683064,"marketCap":5277424965},{"date":"2024-05-31","current":15.007626,"twenty":-7.81017,"median":6.732825,"eighty":12.75491,"marketCap":5282684420},{"date":"2024-06-07","current":14.981478,"twenty":-7.81017,"median":6.732825,"eighty":12.826376,"marketCap":5273480373},{"date":"2024-06-14","current":14.965292,"twenty":-7.835061,"median":6.699881,"eighty":12.854653,"marketCap":5267782630},{"date":"2024-06-21","current":15.053696,"twenty":-7.859952,"median":6.696926,"eighty":12.903973,"marketCap":5298901073},{"date":"2024-06-28","current":15.257899,"twenty":-7.926764,"median":6.670331,"eighty":12.934444,"marketCap":5370780294},{"date":"2024-07-05","current":15.332607,"twenty":-7.926764,"median":6.670331,"eighty":13.078605,"marketCap":5397077570},{"date":"2024-07-12","current":15.560467,"twenty":-7.926764,"median":6.670331,"eighty":14.67393,"marketCap":5477284261},{"date":"2024-07-15","current":16.031128,"twenty":-7.926764,"median":6.670331,"eighty":14.798941,"marketCap":5642957098},{"date":"2024-08-02","current":12.046137,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5986929872},{"date":"2024-08-09","current":11.643786,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5786961567},{"date":"2024-08-16","current":11.960789,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5944512353},{"date":"2024-08-23","current":12.044395,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5986064208},{"date":"2024-08-30","current":12.267342,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6096869157},{"date":"2024-09-06","current":11.844961,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5886945719},{"date":"2024-09-13","current":11.837994,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5883483065},{"date":"2024-09-20","current":12.877836,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6400284270},{"date":"2024-09-27","current":12.605247,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6264807907},{"date":"2024-10-04","current":12.39275,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6159196940},{"date":"2024-10-11","current":12.762878,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6343150468},{"date":"2024-10-18","current":12.754684,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":6339078000},{"date":"2024-10-25","current":12.285395,"twenty":-8.0879,"median":6.543636,"eighty":14.889338,"marketCap":5872418977},{"date":"2024-10-31","current":13.170128,"twenty":-8.0879,"median":6.543636,"eighty":14.807159,"marketCap":6295321107},{"date":"2024-11-08","current":14.050437,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6716108726},{"date":"2024-11-15","current":14.657363,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":7006219587},{"date":"2024-11-22","current":14.262772,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6817605237},{"date":"2024-11-29","current":14.937823,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":7140279562},{"date":"2024-12-06","current":14.566236,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6962660668},{"date":"2024-12-13","current":14.75026,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":7050624311},{"date":"2024-12-20","current":13.771746,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6582894555},{"date":"2024-12-27","current":14.153066,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6765165373},{"date":"2025-01-03","current":13.844294,"twenty":-8.107223,"median":6.538343,"eighty":13.266011,"marketCap":6617572530},{"date":"2025-01-10","current":14.016817,"twenty":-8.126546,"median":6.509878,"eighty":13.206393,"marketCap":6700038445},{"date":"2025-01-17","current":14.647631,"twenty":-8.126546,"median":6.509878,"eighty":13.206393,"marketCap":7001567664},{"date":"2025-01-24","current":14.644977,"twenty":-8.126546,"median":6.509878,"eighty":13.206393,"marketCap":7000298957},{"date":"2025-01-31","current":14.36894,"twenty":-8.126546,"median":6.509878,"eighty":13.206393,"marketCap":6868353493},{"date":"2025-02-07","current":13.879683,"twenty":-8.126546,"median":6.509878,"eighty":13.206393,"marketCap":6634488615},{"date":"2025-02-14","current":13.862207,"twenty":-8.03386,"median":6.543636,"eighty":13.316137,"marketCap":6778619352},{"date":"2025-02-21","current":14.292524,"twenty":-7.746632,"median":6.652028,"eighty":13.787317,"marketCap":6989043992},{"date":"2025-02-28","current":13.739137,"twenty":-7.30351,"median":6.732825,"eighty":13.829167,"marketCap":6718437905},{"date":"2025-03-07","current":13.320009,"twenty":-6.938007,"median":7.55689,"eighty":13.830759,"marketCap":6513484306},{"date":"2025-03-14","current":11.737306,"twenty":-6.885604,"median":7.691962,"eighty":13.830759,"marketCap":5739542480},{"date":"2025-03-21","current":11.989848,"twenty":-6.794229,"median":7.780156,"eighty":13.830759,"marketCap":5863035670},{"date":"2025-03-28","current":12.289466,"twenty":-6.704491,"median":7.818294,"eighty":13.830759,"marketCap":6009548949},{"date":"2025-04-04","current":11.830222,"twenty":-6.612788,"median":7.905144,"eighty":13.830759,"marketCap":5784978738},{"date":"2025-04-11","current":11.83449,"twenty":-6.460167,"median":7.944627,"eighty":13.830628,"marketCap":5787065822},{"date":"2025-04-17","current":11.790103,"twenty":-6.392044,"median":7.965682,"eighty":13.830628,"marketCap":5765360151},{"date":"2025-04-25","current":11.457658,"twenty":-6.145958,"median":8.001039,"eighty":13.830759,"marketCap":5751744390},{"date":"2025-05-02","current":11.438717,"twenty":-5.907983,"median":8.021733,"eighty":13.830759,"marketCap":5742236008},{"date":"2025-05-09","current":12.069535,"twenty":4.422322,"median":8.052268,"eighty":13.830759,"marketCap":6058906475},{"date":"2025-05-16","current":12.972115,"twenty":4.465495,"median":8.071753,"eighty":13.830759,"marketCap":6512001555},{"date":"2025-05-23","current":12.379179,"twenty":4.482002,"median":8.092411,"eighty":13.830759,"marketCap":6214347853},{"date":"2025-05-30","current":12.411296,"twenty":4.504369,"median":8.124987,"eighty":13.830759,"marketCap":6230470762},{"date":"2025-06-06","current":12.205416,"twenty":4.52924,"median":8.150819,"eighty":13.830759,"marketCap":6127118782},{"date":"2025-06-13","current":12.324003,"twenty":4.54414,"median":8.183784,"eighty":13.830759,"marketCap":6186649522},{"date":"2025-06-20","current":12.475531,"twenty":4.557695,"median":8.223114,"eighty":13.830891,"marketCap":6262716580},{"date":"2025-06-27","current":13.078349,"twenty":4.57381,"median":8.253849,"eighty":13.830891,"marketCap":6565331177},{"date":"2025-07-03","current":14.129163,"twenty":4.586262,"median":8.30557,"eighty":13.858624,"marketCap":7092839683},{"date":"2025-07-11","current":14.494806,"twenty":4.600504,"median":8.337941,"eighty":13.890852,"marketCap":7276392799},{"date":"2025-07-18","current":14.164574,"twenty":4.608827,"median":8.434859,"eighty":13.981782,"marketCap":7110616224},{"date":"2025-07-25","current":14.307417,"twenty":4.625011,"median":8.858999,"eighty":14.002789,"marketCap":7225245354},{"date":"2025-08-01","current":14.354265,"twenty":4.633104,"median":9.160989,"eighty":14.049906,"marketCap":7248903923},{"date":"2025-08-08","current":14.19918,"twenty":4.650193,"median":9.572878,"eighty":14.097858,"marketCap":7170585902},{"date":"2025-08-15","current":14.709669,"twenty":4.666003,"median":9.666427,"eighty":14.127845,"marketCap":7428382721},{"date":"2025-08-22","current":14.573161,"twenty":4.709831,"median":9.71638,"eighty":14.151964,"marketCap":7359446547},{"date":"2025-08-29","current":15.114344,"twenty":4.783503,"median":9.76815,"eighty":14.198571,"marketCap":7632743808},{"date":"2025-09-05","current":15.23712,"twenty":4.812786,"median":9.833544,"eighty":14.238885,"marketCap":7694745575},{"date":"2025-09-12","current":15.312239,"twenty":4.861125,"median":10.041985,"eighty":14.314092,"marketCap":7732680866},{"date":"2025-09-19","current":14.993992,"twenty":4.931659,"median":10.156878,"eighty":14.354103,"marketCap":7571965760},{"date":"2025-09-26","current":14.909987,"twenty":4.960305,"median":10.2309,"eighty":14.420027,"marketCap":7529543499},{"date":"2025-10-03","current":15.384936,"twenty":4.977731,"median":10.32899,"eighty":14.468748,"marketCap":7769392438},{"date":"2025-10-10","current":14.883332,"twenty":4.997531,"median":10.44025,"eighty":14.503112,"marketCap":7516082589},{"date":"2025-10-17","current":14.752479,"twenty":5.035793,"median":10.493382,"eighty":14.525335,"marketCap":7450001759},{"date":"2025-10-24","current":12.89259,"twenty":5.054716,"median":10.599398,"eighty":14.539205,"marketCap":6472080000},{"date":"2025-10-31","current":13.625069,"twenty":5.097183,"median":10.658452,"eighty":14.539205,"marketCap":6839784859},{"date":"2025-11-07","current":13.479489,"twenty":5.12209,"median":10.73345,"eighty":14.539205,"marketCap":6766703333},{"date":"2025-11-14","current":13.617026,"twenty":5.133219,"median":10.893348,"eighty":14.539205,"marketCap":6835747206},{"date":"2025-11-21","current":13.070093,"twenty":5.152815,"median":11.090483,"eighty":14.539205,"marketCap":6561186775},{"date":"2025-11-28","current":13.873602,"twenty":5.177781,"median":11.196803,"eighty":14.539205,"marketCap":6964548349},{"date":"2025-12-05","current":14.478446,"twenty":5.19145,"median":11.302112,"eighty":14.539205,"marketCap":7268179885},{"date":"2025-12-12","current":15.927014,"twenty":5.207168,"median":11.404144,"eighty":14.629582,"marketCap":7995361262},{"date":"2025-12-19","current":15.296433,"twenty":5.254517,"median":11.451225,"eighty":14.655417,"marketCap":7678809236},{"date":"2025-12-26","current":15.906907,"twenty":5.265027,"median":11.491086,"eighty":14.698585,"marketCap":7985267129},{"date":"2026-01-02","current":15.393755,"twenty":5.303504,"median":11.530528,"eighty":14.710447,"marketCap":7727664842},{"date":"2026-01-09","current":15.285172,"twenty":5.326043,"median":11.631919,"eighty":14.756356,"marketCap":7673156521},{"date":"2026-01-16","current":15.624593,"twenty":5.335095,"median":11.673876,"eighty":14.821626,"marketCap":7843545494},{"date":"2026-01-23","current":15.790281,"twenty":5.381631,"median":11.714373,"eighty":14.842245,"marketCap":7926721154},{"date":"2026-01-30","current":15.476599,"twenty":5.397735,"median":11.740952,"eighty":14.909825,"marketCap":7769252672},{"date":"2026-02-06","current":17.236437,"twenty":5.43372,"median":11.783021,"eighty":14.940109,"marketCap":8652691236},{"date":"2026-02-13","current":16.435376,"twenty":5.467946,"median":11.830222,"eighty":14.977245,"marketCap":8201252704},{"date":"2026-02-20","current":17.329797,"twenty":5.50631,"median":11.845396,"eighty":14.992461,"marketCap":8647568653},{"date":"2026-02-27","current":17.630044,"twenty":5.529122,"median":11.868324,"eighty":15.006515,"marketCap":8797392028},{"date":"2026-03-06","current":16.622636,"twenty":5.543836,"median":11.926274,"eighty":15.027061,"marketCap":8294695177},{"date":"2026-03-13","current":14.692322,"twenty":5.566305,"median":11.961621,"eighty":15.051953,"marketCap":7331468705},{"date":"2026-03-20","current":15.122092,"twenty":5.582426,"median":12.000539,"eighty":15.06114,"marketCap":7545923966},{"date":"2026-03-27","current":15.704285,"twenty":5.607776,"median":12.030258,"eighty":15.075828,"marketCap":7836438314}],"updateTime":1774824175473},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"R\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618396674","title":"Press Release: Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618396674","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618396674?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:02","pubTimestamp":1773086520,"startTime":"0","endTime":"0","summary":"- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment -. \"The pace of progress at Alpha Tau today is unlike anything we've ever seen before,\" said Alpha Tau Chief Executive Officer Uzi Sofer. \"With a slew of meaningful announcements in the past few months, culminating most recently with our receipt of marketing approval in Japan, our first outside of Israel, and with multiple meaningful milestones targeted for the coming months, we remain laser focused on execution. Clinical trial progress remains our highest priority, with an astounding five clinical trials approved in parallel in the U.S. At the same time, we continue to build out our manufacturing capabilities in New Hampshire as well as our pre-commercial preparations, while entertaining multiple tracks of strategic dialogue with partners who show increas","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","IDE","BK4082","R","DRTS","BK4232","ORR"],"gpt_icon":0},{"id":"2618790671","title":"Press Release: Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2618790671","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618790671?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086460,"startTime":"0","endTime":"0","summary":"Trials for DT-216P2  and DT-168  Ongoing; DT-818  Dosing in Patients Expected in the First Half of 2026. Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution. CARLSBAD, Calif., March 09, 2026  -- Design Therapeutics, Inc. , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported fourth quarter and full year 2025 financial results and highlighted business updates and upcoming milestones across its GeneTAC portfolio.\"The fourth quarter capped a year of strong execution and meaningful progress across our GeneTAC portfolio,\" said Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics. \"We enter 2026 with three clinical programs advancing toward important milestones, including the planned initiation of patient dosing in our Phase 1 trial of DT-818 in DM1 in the first half of the year and anticipated data from DT-216P2 in FA and DT-168 in FECD in the second half of 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4130","BK4505","BK4535","BK4232","DSGN","BK4022","BK4139","FA","R"],"gpt_icon":0},{"id":"2618671711","title":"Press Release: MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures","url":"https://stock-news.laohu8.com/highlight/detail?id=2618671711","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618671711?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:01","pubTimestamp":1773086460,"startTime":"0","endTime":"0","summary":"-- Initial MGC026  Phase 1 results in mid-2026. -- Initial MGC028  Phase 1 results in second half of 2026. -- Lorigerlimab Phase 2 LINNET study update in mid-2026. -- IND submission for MGC030, a first-in-class TOP1i-based ADC, on track for. MacroGenics is developing potential best-in-class or first-in-class antibody-drug conjugates  that leverage its protein engineering expertise and incorporate potent glycan-linked exatecan payloads designed to enable an expanded therapeutic window. The proprietary drug-linker platform is licensed from Synaffix B.V., a Lonza company.MacroGenics' two clinical-stage ADC programs, MGC026 and MGC028, have demonstrated acceptable safety profiles to date, with no observations of interstitial lung disease, as well as encouraging early evidence of anti-tumor activity by Response Evaluation Criteria in Solid Tumors .in tumorigenesis and cancer progression and is overexpressed in multiple","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGNX","BK4022","BK4139","PROC","R","BK4007","BK4232","IND"],"gpt_icon":0},{"id":"2618785576","title":"Press Release: Park Aerospace Corp. Declares Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2618785576","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618785576?lang=en_us&edition=fundamental","pubTime":"2026-03-10 00:04","pubTimestamp":1773072240,"startTime":"0","endTime":"0","summary":"NEWTON, Kan., March 09, 2026  -- The Board of Directors of Park Aerospace Corp.  has declared a regular quarterly cash dividend of $0.125 per share payable May 4, 2026 to shareholders of record at the close of business on April 2, 2026.Park has paid 41 consecutive years of uninterrupted regular, quarterly cash dividends, without ever skipping a dividend payment or reducing the amount of the dividend.The Company has paid $611.0 million in cash dividends, or $29.85 per share, since the beginning of the Company's 2005 fiscal year.Contact: Donna D'Amico-Annitto  486 North Oliver Road, Bldg. Z","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","03160","BK4544","BK4099","BK4555","BK4585","BK4187","ARKG","R","BK4588","BK4022","BK4232","TM","PKE"],"gpt_icon":0},{"id":"2618627897","title":"Press Release: Progressive Announces Quarterly Common Share Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2618627897","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618627897?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:47","pubTimestamp":1773067620,"startTime":"0","endTime":"0","summary":"MAYFIELD VILLAGE, OHIO, March 09, 2026  -- On March 6, 2026, the Board of Directors of The Progressive Corporation  declared a $0.10 per common share dividend, payable April 10, 2026, to shareholders of record at the close of business on April 2, 2026.Progressive Insurance  makes it easy to understand, buy and use car insurance, home insurance, and other protection needs. Progressive offers choices so consumers can reach us however it's most convenient for them -- online at progressive.com, by phone at 1-800-PROGRESSIVE, via the Progressive mobile app, or in-person with a local agent.Progressive provides insurance for personal and commercial autos and trucks, motorcycles, boats, recreational vehicles, and homes; it is the second largest personal auto insurer in the country, a leading seller of commercial auto, motorcycle, and boat insurance, and one of the top 15 homeowners insurance carriers.Founded in 1937, Progressive continues its long history of offering shopping tools and service","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1069347547.HKD","LU1585245621.USD","LU1481011671.HKD","LU1718418525.SGD","SGXZ23171101.USD","LU1235295455.SGD","R","LU1366192091.USD","LU0742537680.HKD","SG9999004303.SGD","LU1509826696.USD","LU0289960550.SGD","LU1599440770.SGD","LU0175139822.USD","LU0320765489.SGD","BK4107","LU1430594728.SGD","LU0070302665.USD","IE00B4JS1V06.HKD","IE0005OL40V9.USD","LU0354030511.USD","LU0731783394.SGD","IE00B7KXQ091.USD","BK4232","IE00BN29S564.USD","IE0004445015.USD","IE00BKVL7J92.USD","SG9999003800.SGD","LU0731783048.USD","IE00BFSS7M15.SGD","LU1035773651.USD","LU2355687059.USD","LU0353189680.USD","LU1481011911.USD","LU0138981039.USD","LU1983260115.SGD","IE0004445239.USD","LU0772969993.USD","LU0208291251.USD","IE00B775H168.HKD","PGR","IE00BJJMRX11.SGD","LU0170899867.USD","BK4533","LU0354030438.USD","LU2087625088.SGD","BK4585","IE00BJJMRY28.SGD","BK4588","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2618162553","title":"Press Release: Mineros S.A. to Acquire a Gold Exploration Project in Tolima, Colombia","url":"https://stock-news.laohu8.com/highlight/detail?id=2618162553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618162553?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:01","pubTimestamp":1773057660,"startTime":"0","endTime":"0","summary":"Mineros S.A.   has entered into a definitive agreement to acquire a 100% interest in a gold exploration project in the Department of Tolima, Colombia from a subsidiary of AngloGold Ashanti PLC  through the acquisition of all the outstanding shares of AngloGold Ashanti Colombia S.A.S. .This transaction reflects Mineros' long-standing conviction in Colombia as a jurisdiction for responsible, well-governed mining. As a Colombian operator with decades of history in the country, Mineros brings deep local knowledge, cultural competency, and an established track record of constructive engagement with communities and authorities. The Company believes that assets of this nature are best stewarded by operators with strong domestic roots, a long-term perspective, and a commitment to aligning development pathways with local priorities.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNSAF","MSA","LU2125909916.SGD","BK4017","LU1815336091.USD","BK4022","LU0053671581.USD","LU2125909759.SGD","LU0728928796.USD","BK4232","BK4143","LU0757428866.USD","LU1923622291.USD","LU2211815571.USD","R"],"gpt_icon":0},{"id":"2618567625","title":"Press Release: Byrna Technologies Announces Preliminary Fiscal First Quarter Revenues of $29.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618567625","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618567625?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:00","pubTimestamp":1773057600,"startTime":"0","endTime":"0","summary":"ANDOVER, Mass., March 09, 2026  -- Byrna Technologies Inc.  , a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today announced select preliminary financial results for the fiscal first quarter ended February 28, 2026.Based on preliminary unaudited results, Byrna expects total revenue for the fiscal first quarter of 2026 to be approximately $29.0 million, an increase of 11% compared to $26.2 million in the fiscal first quarter of 2025. The Company also ended the quarter with approximately $1.1 million in backlog, slightly above typical first-quarter levels due to shipment timing at quarter-end.First quarter revenue reflects the typical post-holiday seasonal moderation following Byrna's strong holiday-driven fourth quarter.During the quarter, Byrna continued to generate sales across its multiple distribution channels, including its direct-to-consumer platform and expanding retail footprint,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4232","BYRN","BK4022","BK4187"],"gpt_icon":0},{"id":"2618738628","title":"Press Release: Korro Announces Oversubscribed $85 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2618738628","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618738628?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:30","pubTimestamp":1773055800,"startTime":"0","endTime":"0","summary":"-- Financing led by new investor Venrock Healthcare Capital Partners, with. -- Proceeds support the achievement of value inflection points for multiple. RNA editing programs including reporting clinical data for:. -- KRRO-121 for hyperammonemia in patients with urea cycle disorders. -- Company expects proceeds to extend cash runway into the second half of. The PIPE financing was led by Venrock Healthcare Capital Partners, and participation from new and existing investors, including ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset Management, Driehaus Capital Management, Kalehua Capital, Lynx1 Capital Management, Nantahala Capital, and New Enterprise Associates.The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the sec","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","BK4505","BK4588","IE0009354923.USD","PIPE","BK4585","KRRO","BK4139","R","RNA"],"gpt_icon":0},{"id":"2618640488","title":"Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618640488","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618640488?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"LEGEND pivotal cohort update planned for a spring 2026 medical conference. 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026. Biologics License Application  submission for detalimogene planned for 2H 2026. Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028. enGene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2026, and provided a business update.\"As data from LEGEND's pivotal cohort in high-risk, BCG-unresponsive NMIBC continues to mature, we look forward to providing an update at a spring medical conference,\" said Ron Cooper, President and Chief Executive Officer, enGene. \"On the heels of our successful November follow-on offering, we entered 2026 in a position of financial strength and ready to execute. With RMAT and CDRP designations for detalimogene, we are in active dialogue with the FDA to ensure regulatory ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCG","LU0971096721.USD","BK4585","BK4006","CMC","BK4232","ENGN","BK4139","HTGC","LU2746668974.SGD","BK4135","LU2746668461.USD","TRAE","BK4161","LU2237443549.SGD","LU2237443465.HKD","BK4022","LU0267386448.USD","IE00B1BXHZ80.USD","LU2237443622.USD","BK4588","IE00BFXG1179.USD","LABU","LU1363072403.SGD","CR","LU2237443978.SGD","IE00BHPRN162.USD","LU2237443382.USD","IE00BZ1G4Q59.USD","LU2237443895.HKD","DDX","R","LU0882574139.USD","IE00BKVL7J92.USD","LU0170899867.USD","LU0149725797.USD"],"gpt_icon":0},{"id":"2618264227","title":"Press Release: Chemtrade Logistics Income Fund Announces Filing of Audited Financial Statements for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2618264227","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618264227?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:15","pubTimestamp":1773051300,"startTime":"0","endTime":"0","summary":"Chemtrade operates a diversified business providing industrial chemicals and services to customers in North America and around the world. Chemtrade is one of North America's largest suppliers of sulphuric acid, spent acid processing services, inorganic coagulants for water treatment, sodium chlorate, sodium nitrite and sodium hydrosulphite. Chemtrade is also one of the largest producers of high purity sulphuric acid for the semiconductor industry in North America. Chemtrade is a leading regional supplier of sulphur, chlor-alkali products, and zinc oxide. Additionally, Chemtrade provides turnkey water treatment solutions, as well as industrial services such as processing by-products and waste streams.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","CGIFF","BK4232","BK4090","BK4022"],"gpt_icon":0},{"id":"2618528642","title":"Press Release: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy(R) (epinephrine nasal spray) Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2618528642","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618528642?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:00","pubTimestamp":1773050400,"startTime":"0","endTime":"0","summary":"neffy delivers $72.2 million of U.S. net product revenue in first full year. Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026. Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even. \"2025 was an important year for ARS Pharma as we established neffy as a differentiated, scalable epinephrine treatment of choice. We have built a strong base business with initial prescriptions expected to begin renewing in 2026 as product reaches expiration. This shift towards renewals, combined with continued growth in new neffy patients, positions us to accelerate market share expansion,\" said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma.and $0.9 million in supply revenue from partners. The cash value of. and $0.1 million was recorded to the financing liability on the company's. collaboration revenue, and $2.4 million from supply agreements. The cash","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4500","CHMP","BK4585","R","BK4588","SPRY","ALK","BK4081","BK4008","EMA","BK4022","BK4087","BK4139"],"gpt_icon":0},{"id":"2617653634","title":"Press Release: Alliance Laundry Systems Acquires Super Laundry in New York","url":"https://stock-news.laohu8.com/highlight/detail?id=2617653634","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617653634?lang=en_us&edition=fundamental","pubTime":"2026-03-07 06:01","pubTimestamp":1772834460,"startTime":"0","endTime":"0","summary":"RIPON, Wis., March 6, 2026 /PRNewswire/ -- Alliance Laundry Systems, a global provider of commercial laundry equipment, has acquired the distribution assets of Super Laundry.\"We are delighted by what this acquisition means to customers in the Northeast,\" said Mike Hand, Vice President, North America Commercial Central and East, Alliance Laundry Systems. \"Super is the perfect complement to our acquisition of Metropolitan Laundry, late last year. I'm beyond confident that these unified teams will bring truly next-level service and support.\". Following the acquisition, Super's Melville, NY operations will become part of the Alliance Laundry Systems Distribution-New York Metro Office in South Richmond Hill, NY.Super Laundry's New York location opened in the 1980s. Leveraging the respected Speed Queen and UniMac brands, Super Laundry built a loyal customer base among laundromat owners, and on-premises laundry managers.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Alliance Laundry Systems Acquires Super Laundry in New York","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","R","BK4232"],"gpt_icon":0},{"id":"2617658805","title":"Press Release: RBI Recommends Shareholders Reject NYSB's \"Mini-tender Offer\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2617658805","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617658805?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:15","pubTimestamp":1772831700,"startTime":"0","endTime":"0","summary":"MIAMI, March 6, 2026 /PRNewswire/ - Restaurant Brands International Inc.    has been notified of an unsolicited mini-tender offer made by New York Stock and Bond LLC  to purchase up to 100,000 RBI common shares, or approximately 0.03% of the company's outstanding common shares, at a price of US$43.60 per share. NYSB's offer price of US$43.60 represents a discount of 34.92% to the NYSE closing price of US$66.99 for RBI common shares on January 30, 2026, the last trading day before the mini-tender offer was commenced. RBI cautions shareholders that the mini-tender offer has been made at a price significantly below the market price for RBI shares.RBI does not endorse this unsolicited offer, has no association with NYSB or its offer, and recommends that shareholders do not tender their shares to the offer.Restaurant Brands International Inc. is one of the world's largest quick service restaurant companies with nearly $47 billion in annual system-wide sales and over 33,000 restaurants in mo","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","QSR","R","BK4209","LU0149725797.USD","CSA","IE00BHPRN162.USD"],"gpt_icon":0},{"id":"2617160639","title":"Press Release: Orexo changes the organizational structure and management team to increase focus on development of new products","url":"https://stock-news.laohu8.com/highlight/detail?id=2617160639","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617160639?lang=en_us&edition=fundamental","pubTime":"2026-03-06 23:30","pubTimestamp":1772811000,"startTime":"0","endTime":"0","summary":"UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB ,  , today announces changes to its organizational structure and management team. The changes are a result of the divestment of Zubsolv in the US market and focus on advancing development programs and the AmorphOX technology.Maintaining commercial and US market competence is important to ensure new products are developed to address unmet customer needs. Lisa Moore, who has been part of Orexo's US leadership team since May 2024, will assume a new responsibility as Senior Vice President, Products and Portfolio Strategy. In her new role, she will be responsible for driving the long-term product vision for the development candidates, ensuring that the portfolio meets customer needs and that investment decisions support business growth.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07399","BK4232","MSTY.UK","BK4585","MSOO","3LMI.UK","MSTX","MSTW","07799","BK4600","BK4007","BK4595","MSDD","ORXOY","LMI3.UK","SMST","BK4023","MSTP","SMI3.UK","BK4588","R","MST","09799","MSTK","MSTY","APED","3SMI.UK","09399","MSTZ","WNTR","IMST","BK4596","MTYY","MSII","BK4022","BK4516","MSST"],"gpt_icon":1},{"id":"2617363612","title":"Press Release: Broadridge Declares Quarterly Dividend of $0.975 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2617363612","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617363612?lang=en_us&edition=fundamental","pubTime":"2026-03-06 22:57","pubTimestamp":1772809020,"startTime":"0","endTime":"0","summary":"NEW YORK, March 6, 2026 /PRNewswire/ -- Broadridge Financial Solutions, Inc.  announced that its Board of Directors has declared a quarterly cash dividend of $0.975 per share. The dividend is payable on April 8, 2026 to stockholders of record at the close of business on March 16, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1228905540.USD","IE0009354923.USD","LU1228905037.USD","BR","BK4585","LU0545562505.USD","BK4022","LU0390134368.USD","BK4106","BK4588","BK4232","BK4226","BK4548","R","IE0034235188.USD"],"gpt_icon":0},{"id":"2617805916","title":"Press Release: Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2617805916","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617805916?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:45","pubTimestamp":1772801100,"startTime":"0","endTime":"0","summary":"- 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 -. - Dosing in Phase 2 trial of atebimetinib + Libtayo in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 -. - Ended 2025 with $217 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 -. NEW YORK, March 06, 2026  -- Immuneering Corporation , a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","R","BK4097","BK4563","EMA","IMRX","BK4539","BK4081","BK4232","OS","BK4022"],"gpt_icon":0},{"id":"2617876356","title":"Press Release: CARsgen Therapeutics Announces 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617876356","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617876356?lang=en_us&edition=fundamental","pubTime":"2026-03-06 20:04","pubTimestamp":1772798640,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results.-- Cash and cash equivalents were around RMB1,123 million as of December 31,2025. Cash and cash equivalents at the end of 2026 are expected to be not. less than RMB1,000 million. The net loss for the year ended December 31,2025 was RMB103 million, representing a decrease of approximately 87%. compared to the year ended December 31, 2024. In light of operational. factors such as the changes in operating cash flow, we expect to have. -- During 2025, CARsgen has received a total of 218 confirmed orders of. zevor-cel from its commercialization partner Huadong Medicine. In. December 2025, zevor-cel has been included in China's Commercial Health. -- The Center for Drug Evaluation  of the National Medical Products.  and granted Priority Review for satri-cel. The results of satri-cel. confirmatory Phase II trial i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK4195","BK4097","BK0188","BK4588","CDE","OS","BK4604","BK4007","CAR","BK4539","BK0132","BK0196","BK0175","03160","BK1161","BK1574","LU1223082196.USD","BK4139","BK4022","BK0209","BK4211","BK4232","LENZ","BK4099","LU1223082519.USD","BK4585","TM","LU2328871848.SGD","LU1223083913.SGD","02171","BK1587","BK4555","R","BK0187","PFS","BK4017","000963","BK1585","BK0183","BK4230"],"gpt_icon":0},{"id":"2617587571","title":"Press Release: Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2617587571","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617587571?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:56","pubTimestamp":1772747760,"startTime":"0","endTime":"0","summary":"Hyperfine, Inc. , the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain--the Swoop system--today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, March 18, 2026. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.For more information about the Swoop system, please visit HyperfineMRI.com.Hyperfine, Inc.  is the groundbreaking health technology company that has redefined brain imaging with the Swoop system--the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Cat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4232","BK4082","BK4022","HYPR"],"gpt_icon":0},{"id":"2617576153","title":"Press Release: Bel Fuse Inc. Announces Acquisition of dataMate, an advanced ethernet and broadband business, from Methode Electronics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2617576153","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617576153?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:15","pubTimestamp":1772745300,"startTime":"0","endTime":"0","summary":"WEST ORANGE, N.J., March 05, 2026  -- Bel Fuse Inc.  , a leading global manufacturer of products that power, protect and connect electronic circuits, is pleased to announce the acquisition of dataMate, a leading solutions provider of advanced ethernet and broadband technologies, from Methode Electronics Inc. Bel acquired dataMate for $16 million, including $1 million of deferred consideration. With annual sales of approximately $18 million and operating margins in line with Bel's corporate averages, the dataMate acquisition is expected to be immediately accretive to Bel's financials.Beyond product and market expansion, the acquisition brings expansion to Bel's US-based manufacturing capabilities, including R&D, sales and product management functions. Joe Berry, President of the Magnetics Division at Bel, commented: \"The acquisition of dataMate is expected to expand Bel's leadership in networking solutions. The innovative technologies and talented engineering team will enable Bel to del","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BELFA","BK4145","BK4022","BELFB","BK4148","MEI","BK4232","R"],"gpt_icon":0},{"id":"2617866576","title":"Press Release: Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2617866576","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617866576?lang=en_us&edition=fundamental","pubTime":"2026-03-06 05:05","pubTimestamp":1772744700,"startTime":"0","endTime":"0","summary":"Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus  in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026. Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care. Expanded Antiviral Pipeline with New Hepatitis E Virus  Program; Lead Product Candidate AT-587 Expected to Enter Clinic Mid-2026. Atea continues to advance its global Phase 3 program evaluating the fixed-dose combination  of bemnifosbuvir  and ruzasvir  for the treatment of chronic HCV. The global Phase 3 program consists of two open-label controlled trials: C-BEYOND in North America and C-FORWARD outside North America. In 2025, Atea advanced enrollment across both trials. The Company completed C-BEYOND enrollment in December 2025 with over 880 patients and C-FORWARD is expected to complete enrollment mid-2","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","CTA","BK4007","IND","R","BK4022","BK4085","AVIR","DDI"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}